In conclusion, we propose that tumour stromal architecture may affect the response of tumour vasculature to VEGFR TKI treatment, and that acute change in tumour perfusion may be predictive of tumour response to VEGFR TKI in NSCLC. The gene discussed is KDR; the disease is neoplasm.